Trevi Therapeutics, Inc.
Financials
Valuation Metrics
Trevi Therapeutics, Inc.'s Market Cap is $2.12B. At end of 2025 it was $1.82B. Ranked #1970 of 3,121 in US market (top 63%), #748 of 1,463 on NASDAQ (top 51%), #131 of 266 in Pharmaceuticals, Biotechnology & Life Sciences (top 49%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $2.12B | US#1,970/3,121 Sec#131/266 |
| Revenue | $0.00 | US#2,889/3,121 Sec#196/266 |
| Net Income | $-51M | US—/3,121 Sec—/266 |
| Total Assets | $331M | US#2,895/3,121 Sec#202/266 |
| Net Assets | $322M | US#2,494/3,121 Sec#155/266 |
| Employees | 34 | US#2,746/3,121 Sec#218/266 |
| Value | ||
| P/B | 6.60x | US#2,429/3,121 Sec#168/266 |
| FCF Yield | -1.86% | US—/3,121 Sec—/266 |
| Profitability | ||
| ROE | -15.90% | US#2,441/3,121 Sec#91/266 |
| ROA | -15.46% | US#2,753/3,121 Sec#120/266 |
| Financial Health | ||
| Debt Ratio | 2.80% | US#25/3,121 Sec#6/266 |
| Total Debt | $605000.00 | US#2,999/3,121 Sec#252/266 |
| FCF | $-39M | US#2,502/3,121 Sec#108/266 |
| Cash | $54M | US#2,552/3,121 Sec#223/266 |
| Current Ratio | 37.28x | US#70/3,121 Sec#7/266 |
| Performance | ||
| 1Y Return | 75.06% | US#255/3,121 Sec#68/266 |
| 1M Return | -20.52% | US#2,955/3,121 Sec#239/266 |
| From 52W High | -26.06% | US#1,775/3,121 Sec#135/266 |
| 1Y MDD | -29.50% | US#1,375/3,121 Sec#87/266 |
| Trading | ||
| Volume | 1,939,209 shares | US#1,112/3,121 Sec#113/266 |
| Trading Value | $29M | US#1,833/3,121 Sec#143/266 |
| Per Share | ||
| EPS | $-0.36 | US—/3,121 Sec—/266 |
| BPS | $2.26 | US#2,557/3,121 Sec#174/266 |
Company Info
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the advancement and commercialization of Haduvio, a potential treatment for debilitating neurologically mediated conditions. This orally administered, extended-release formulation of nalbuphine is currently undergoing Phase IIb/III clinical trials for chronic pruritus (severe itching) and persistent cough experienced by patients with idiopathic pulmonary fibrosis. Trevi Therapeutics also possesses a licensing agreement with Endo Pharmaceuticals Inc., granting it the rights to develop and market products containing nalbuphine hydrochloride in various formulations. Established in 2011, the company maintains its corporate headquarters in New Haven, Connecticut.